Most Shared

RSS Feeds

Weather Alert

Winter Weather On the Way

A Winter Weather Advisory is in effect for the entire region through Monday afternoon. Snow, some heavy at times will work through the region over the next 24 to 36 hours.  Looks like even into Tuesday some snow showers may linger.  Accumulations are likely and in some cases may exceed 5 to 9" across parts of the region.  Look for some colder air to move in for the beginning of the week as well with temperatures in the 20s for highs. 

WEATHER ALERT


Weather Alert Radar

WJAC 6 News - Search Results

The following is an archived video story. The text content of that video story is available below for reference. The original video has been deleted and is no longer available.

Company approves experimental drug to be given to ill child

By: Lauren Hensley

STATE COLLEGE, Pa. -- Seven-year-old Josh Hardy has been fighting for his life since he was a baby. He's been through four bouts of cancer, has survived, and has been cancer free for two years. But during his last round he had to undergo a bone marrow transplant that weakened his immune system.

Doctors at St. Jude Children's Hospital recommended Josh be treated with a drug that is currently in trial form and has not yet been approved by the Food and Drug Administration. The drug is manufactured by a company called Chimeriz in North Carolina. Josh's family was willing to do whatever it could to get Josh the medicine, so it began a social media campaign.

"The family has advocated for him, the community has advocated for him near and far and there are so many people that are out there to support Josh because no one should let a 7-year-old fight alone," Josh's uncle, Matt Hardy, of State College, said.

Tuesday, the company agreed to move the development of the drug forward. In a statement Chimeriz said:

"...Josh Hardy's story brought to public attention the often-devastating impact of adenovirus infection, and helped accelerate a discussion between the FDA and Chimerix regarding the need for additional clinical development to assess brincidofovir's potential in adenovirus infection. This study is expected to begin with Josh Hardy as the first patient enrolled on Wednesday, March 12, 2014."

Everyone is hash tagging 'Save Josh' and it has just been amazing the outreach and the support near and far to help Josh to get the medication to help him fight this virus," Hardy said.

Read the drug company's full statement here

 
Advertise with us!
Edgar Snyder

Washington Times

Talkers